WASHINGTON - The National Institute of Allergy and Infectious Diseases (NIAID) has scrapped a large-scale HIV vaccine study, known as PAVE 100, and has opted instead to conduct a smaller, more focused trial of the agency's investigational vaccine. (BioWorld Today) Read More